XML 28 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - (Tables)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Schedule of Concentration of Risk, by Risk Factor and Significant Payer For each significant payor and customer, revenue as a percentage of total revenue and accounts receivable as a percentage of total accounts receivable are as follows:
 
 Revenue
 Three Months Ended
March 31,
 20212020
Medicare18 %25 %
Blue Shield12 %12 %
Medicare Advantage12 %13 %
United Healthcare*10 %
*Less than 10%.
 Accounts Receivable
 March 31, 2021December 31, 2020
 
Janssen (SIMPONI®)
25 %35 %
Blue Shield13 %11 %
*Less than 10%.
Disaggregation of Revenue The following table includes the Company's revenues as disaggregated by payor and customer category (in thousands):
 
 Three Months Ended March 31,
 20212020
Revenue:
Healthcare insurers$6,027 $6,062 
Government2,009 2,245 
Client(1)1,965 1,082 
Other(2)286 195 
Janssen (SIMPONI®)
300 — 
Total revenue$10,587 $9,584 
(1)Includes hospitals, other laboratories, etc.
(2)Includes patient self-pay that is immaterial.
Schedule of Restricted Cash and Cash Equivalents Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands): 
 March 31, 2021December 31, 2020
 
Cash and cash equivalents$118,050 $57,448 
Restricted cash100 100 
$118,150 $57,548 
Schedule of Cash and Cash Equivalents Cash, cash equivalents and restricted cash presented in the accompanying condensed statements of cash flows consist of the following (in thousands): 
 March 31, 2021December 31, 2020
 
Cash and cash equivalents$118,050 $57,448 
Restricted cash100 100 
$118,150 $57,548 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
 
 Three Months Ended March 31,
 20212020
Warrants to purchase common stock426,827 436,581 
Common stock options2,041,580 1,630,014 
Restricted stock units185,000 — 
Employee stock purchase plan2,869 2,021 
Total2,656,276 2,068,616